Friday, 16 October 2026European Markets

RALLYE Stock Over 10% Up So Far On Tuesday

Loading stream...

rallye sa, a supermarket operator based in france, noticed a significant increase in its shares defying the general trend in the country's cac 40 index. on tuesday afternoon at 14:17 est, the shares increased by 10.44% to eur0.20, while france's cac 40 index experienced a drop of 1.14%. during monday's session, rallye's shares closed at eur0.19; this places the company's shares at 94.63% below their peak in the last 52-weeks, which was eur3.60.

a year of poor financial performance

rallye's past year has been marked by a highly disappointing financial performance, which has drastically affected its stock. within this period, the company posted an earnings-per-share (eps) figure of -eur4.17 along with a return on equity (roe) score of -71.26%. these figures are significant as they measure how efficiently companies can generate profits from shareholders' investments.

inconsistent trading trends

at present, rallye shares are trading well below both the 50-day moving average (eur1.01) and 200-day moving average (eur2.00). these are key indicators monitored by traders and investors to measure overall stock trends. over the recent past, the trading activity of rallye shares has been characterized by considerable volatility. just over the past week, its shares witnessed huge swings of 2.07%. over the last month, the fluctuation was 10.38%, and 9.35% over the quarter. while such fluctuations can unsettle some investors, they can also provide profitable trading opportunities for others.

increased trading volume

despite the sharp swings in price, rallye's trading volume has seen a minor increase. the most recently reported volume totalled 921,521 shares, which represents a rise of 2.56% from its average volume of 898,503 shares.

a cautionary tale for investors

in summary, despite the recent surge in rallye stock, its overall performance reflects a highly volatile stock that consistently performs below its moving averages and does not show any substantial profitability gains. these factors should be regarded as a warning sign to potential investors.

more news about rallye (ral.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com